Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate

Keren Miller, Rotem Erez, Ehud Segal, Doron Shabat, Ronit Satchi-Fainaro

Research output: Contribution to journalArticlepeer-review

Abstract

A polymer therapeutic designed for combination anticancer and antiangiogenic therapy inhibited the proliferation of prostate carcinoma cells and the proliferation, migration, and tube-formation of endothelial cells. The nanoconjugate was formed from an N-(2- hydroxypropyl)methacrylamide (HPMA) copolymer, the bisphosphonate alendronate (for bone targeting), and the chemotherapy agent paclitaxel (PTX), which is cleaved by cathepsin B (see scheme).

Original languageEnglish
Pages (from-to)2949-2954
Number of pages6
JournalAngewandte Chemie - International Edition
Volume48
Issue number16
DOIs
StatePublished - 6 Apr 2009

Fingerprint

Dive into the research topics of 'Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate'. Together they form a unique fingerprint.

Cite this